Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 117Carboplatin 47Nivolumab 46Paclitaxel 34Cyclophosphamide 34Cisplatin 33Gemcitabine 30atezolizumab 27Specimen Handling 26Magnetic Resonance Spectroscopy 25venetoclax 24Docetaxel 24fludarabine 23Pemetrexed 23Biopsy 22Bevacizumab 22Radiotherapy 21Ipilimumab 21Azacitidine 20Dexamethasone 19Radiosurgery 18durvalumab 17Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × In Situ Hybridization, Fluorescence × 1 year × Clear all
NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

University of Southern California

Phase 2 Terminated
15 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡